About this trial
The purpose of this study is to employ continuous glucose monitoring to measure glucose profiles in newborn infants.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Mother at least 18 years of age
Infants born either appropriate for gestational age (AGA) or large for gestational age (LGA)
Skin fold over superior gluteus area at least 1 inch in thickness as measured by skin calipers
Disqualifiers
Infants born small for gestational age (SGA)
Infant birth weight <2.5 kg
Infant BMI <10th percentile on Olsen chart
Infants born <38 weeks gestation
Trial population
Mother/infant dyads will be admitted at UCSD Jacobs Medical Center for antepartum and postpartum care.
Trial design
Cohort
Prospective
Treatments tested in this trial
Dexcom continuous glucose monitor
DeviceMeasurement of interstitial glucose
Treatment groups
Trial outcomes
Primary outcomes
Time spent with glucose <40 mg/dL
The Dexcom continuous glucose monitors measure interstitial fluid glucose values every 5 minutes. Data obtained from the Dexcom tracings will allow us to quantify how much time both infants with no risk for hypoglycemia (defined here as \<40 mg/dL) and those with risk factors for hypoglycemia spend at a blood glucose of \<40 mg/dL.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of California, San Diego
Lead sponsor
DexCom, Inc.
Collaborator